Journal Browser

► Journal Browser

Special Issue Editor

Dr. Agnieszka Neumann-Podczaska

E-Mail Website
Guest Editor

Department of Palliative Medicine, Poznan University of Medical Sciences, 61-245 Poznan, Poland
Interests: appropriateness of pharmacotherapy in geriatrics; pharmaceutical care; medication use review; pain treatment; education of pharmacists; interdisciplinary care; pharmacist-physician collaboration

Special Issue Information

Dear Colleagues,

Pharmaceutical care is a new, exciting, and challenging vision for pharmacy worldwide. In pharmaceutical care, the pharmacist cooperates with other professionals and the patient in designing, implementing, and monitoring the best therapeutic plan.

Many pharmacists have expressed great enthusiasm for the concept. There is now great hope that pharmaceutical care will serve as a strong stimulus to transform the pharmacist profession into one that is more patient-centered and focused on medication therapy management.

I hope that all pharmacists in all practice settings share the vision of patient-centered care; at the heart of that care there is a unique, irreducible, one-to-one relationship between pharmacist and patient. In this relationship, the patient’s quality of life is paramount.

To transform and strongly enhance the pharmacist profession there is a great need to provide education and conduct research in the area of pharmaceutical care. Therefore, I am pleased to invite you to contribute to this Special Issue.

Potential topics include, but are not limited to:

- Pharmaceutical care as an effective tool to optimize pharmacotherapy;

- Medicines Use Review (MUR), medication therapy management (MTM);

- Adverse drug effects and the pharmacist’s role in prevention;

- Pharmaceutical care as an integral part of the healthcare system;

- Deprescribing and polypharmacy management—case analysis;

- Self-medication and safety aspects;

- The clinical pharmacist as a member of interdisciplinary teams in the hospital setting;

- New services of clinical and hospital pharmacy;

- Pharmacist, physician, and patient perception of pharmaceutical care.

Dr. Agnieszka Neumann-Podczaska
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

MUR
MTM
pharmaceutical care
pharmacist role
pharmacotherapy optimization
clinical pharmacy

Published Papers (2 papers)

Download All Papers

Research

11 pages, 727 KiB

Open AccessArticle

Polypharmacy Management in a Gender Perspective: At the Heart of the Problem: Analysis of Major Cardiac Diseases, SARS-CoV-2 Affection and Gender Distribution in a Cohort of Patients in Internal Medicine Ward

by Filomena Pietrantonio, Angela Ciamei, Antonio Vinci, Tiziana Ciarambino, Elena Alessi, Matteo Pascucci, Michela Delli Castelli, Silvia Zito, Simona Sanguedolce, Marianna Rainone, Jacopo Di Lorenzo, Fabio Vinci, Giulia Laurelli, Claudia Di Iorio, Roberto Corsi, Serafino Ricci, Alessandra Di Berardino, Matteo Ruggeri and Francesco Rosiello

Int. J. Environ. Res. Public Health 2023, 20(9), 5711; https://doi.org/10.3390/ijerph20095711 - 03 May 2023

Cited by 2 | Viewed by 1634

Abstract

Background: COVID-19 patients with any pre-existing major cardio-vascular disease (CVD) are at the highest risk of viral infection and of developing severe disease. The pathophysiological mechanism is characterized by the viral link to angiotensin-converting enzyme 2 (ACE2) and the involvement of the endothelial system with the release of cytokines and the inflicting of direct damage to the myocardium, the induction of microthrombosis, and the initiation of alterations in oxygen diffusion. The aim of the study is to analyze the clinical course and outcomes in patients (gender-stratified) with pre-existing major CVD. Methods: Out of the 1833 (973 M/860 F) patients admitted to the Internal Medicine COVID-19 Unit of “Castelli Hospital”, Lazio, Italy, from 1 January 2021 to 31 December 2021, 600 patients (320 M/280 F) with a mean age of 77 (78.6 M/75.1 F) previously had CVD. Demographic characteristics, length of the stay (LOS) and oxygen therapy were evaluated. Results: All of the CVD COVID-19 patients underwent non-invasive ventilation (NIV). CVD was linked with increased LOS (21 days F/22 M) compared to no CVD (19 days). In total, 32.7% of total patients had major CVD. Conclusions: Timely identification and evaluation of patients with pre-existing major CVD are fundamental for adequate treatment based on gender, severity, state of illness and for risk reduction. Full article

(This article belongs to the Special Issue An Update on Pharmaceutical Care and Drug-Related Issues)

► Show Figures

Figure 1

25 pages, 3270 KiB

Open AccessArticle

Cannabidiol (CBD) Protects Adipose-Derived Mesenchymal Stem Cells (ASCs) against Endoplasmic Reticulum Stress Development and Its Complications

by Anna Kowalczuk, Krzysztof Marycz, Katarzyna Kornicka-Garbowska, Justyna Kornicka, Magdalena Bujalska-Zadrożny and Sylwia Groborz

Int. J. Environ. Res. Public Health 2022, 19(17), 10864; https://doi.org/10.3390/ijerph191710864 - 31 Aug 2022

Cited by 4 | Viewed by 2391

Abstract

Background: Recent studies suggested that individuals with metabolic disorders have altered function of adipocytes and adipose stem cell subpopulations, which impairs tissue homeostasis, promoting insulin resistance and diabetes development. The non-psychoactive phytocannabinoid CBD was found to modulate adipose tissue metabolism, however, its exact role in controlling ASCs’ fate is still poorly understood. Objectives: This investigation aimed to elucidate whether pretreatment of ASCs with CBD can protect against ER stress development and maintain the cytophysiological properties of cells. Methods: Human ASCs were cultured under control and adipogenic conditions. Prior to the experiments, cells in the experimental group were pretreated with CBD following the addition of an ER stress inducer—tunicamycin. After the experiments, the cells were subsequently tested for expression of the apoptotic, ER stress, and anti-inflammatory-related genes using RT-qPCR. Oxidative stress was analysed with flow cytometric assays. Results: Cells pretreated with CBD displayed decreased apoptosis and enhanced proliferation rate. Additionally, the expression of pro-inflammatory cytokines and miRNAs was significantly reduced. The obtained results also demonstrated an obvious reduction in intracellular accumulated ROS and NO, as well as mitigated ER stress through the down-regulation of IRE-1, PERK, CHOP, and ATF6 transcripts upon CBD treatment. Conclusion: The presented data provide the evidence that CBD protects ASCs against ER stress development and its complications and, thus, offers new insights for the management of obesity through the regulation of adipose tissue dynamics. Full article

(This article belongs to the Special Issue An Update on Pharmaceutical Care and Drug-Related Issues)

► Show Figures